Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.
Cancer Lett
; 240(2): 225-33, 2006 Aug 28.
Article
en En
| MEDLINE
| ID: mdl-16271436
This study evaluated the anti-tumor efficacy of combining the RXR agonist, bexarotene, with the PPARgamma agonist, rosiglitazone, in colon cancer. Moser, a human colon cancer cell line, was treated with bexarotene and rosiglitazone alone or in combination and the effect on growth and differentiation were examined. The data demonstrated that the bexarotene/rosiglitazone combination produced greater efficacy in growth inhibition than either single agent. Furthermore, combination treatment acted cooperatively to decrease COX-2 expression and PGE2 synthesis while increasing expression of the differentiation marker, CEA. These findings were confirmed in vivo in a Moser xenograft tumor model. Collectively, our data suggest a potential role for utilizing a combination regimen of a RXR and PPARgamma agonist in the treatment of colon cancer.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Diferenciación Celular
/
Neoplasias del Colon
/
PPAR gamma
/
Receptores X Retinoide
/
Proliferación Celular
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Cancer Lett
Año:
2006
Tipo del documento:
Article
País de afiliación:
Estados Unidos